<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: <z:chebi fb="0" ids="31941">Oxaliplatin</z:chebi> in combination with <z:chebi fb="0" ids="46345">5-fluorouracil</z:chebi> (5-FU) and leucovorin (FOLFOX) is a common chemotherapeutic regimen for advanced <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Here, we present a case of <z:hpo ids='HP_0006530'>interstitial lung disease</z:hpo> associated with FOLFOX therapy </plain></SENT>
<SENT sid="2" pm="."><plain>CASE REPORT: A 74-year-old man with a history of <z:e sem="disease" ids="C0948380" disease_type="Neoplastic Process" abbrv="">metastatic colorectal cancer</z:e> was admitted with a four week history of progressive dyspnoea and evidence of severe <z:hpo ids='HP_0002093'>respiratory failure</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>He had recently completed six cycles of FOLFOX chemotherapy in the months prior to presentation </plain></SENT>
<SENT sid="4" pm="."><plain>Investigations did not reveal convincing evidence of <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> or <z:hpo ids='HP_0002204'>pulmonary embolism</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>CT chest demonstrated widespread <z:hpo ids='HP_0002113'>pulmonary infiltrates</z:hpo> and interlobular septal thickening </plain></SENT>
<SENT sid="6" pm="."><plain>The patient was commenced on both broad spectrum antibiotic therapy and high dose <z:chebi fb="0" ids="50858">corticosteroid</z:chebi> treatment however his <z:hpo ids='HP_0002093'>respiratory failure</z:hpo> continued to progress </plain></SENT>
<SENT sid="7" pm="."><plain>The patient died four days after admission due to <z:hpo ids='HP_0004893'>progressive respiratory failure</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain>Subsequent post-mortem examination demonstrated evidence of <z:e sem="disease" ids="C1262020" disease_type="Disease or Syndrome" abbrv="">diffuse alveolar damage</z:e> without evidence of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> infiltration, <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> or <z:hpo ids='HP_0002204'>pulmonary embolism</z:hpo> </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: Although infrequent, pulmonary toxicity can occur in association with FOLFOX therapy </plain></SENT>
<SENT sid="10" pm="."><plain>Cessation of therapy and prompt initiation of <z:chebi fb="0" ids="50858">corticosteroids</z:chebi> may improve outcomes </plain></SENT>
</text></document>